Benjamin Rush Institute · Aug 25, 2026
Sally Pipes: "The Sneaky, Unregulated Dangers of Copycat GLP-1 Drugs"
0Sign in to vote or save
When unauthorized, mass-market compounded copies siphon sales from innovators during their exclusivity period, they reduce the resources available to develop the next generation of medicines.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.